{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:19:24Z","timestamp":1790936364898,"version":"4.1.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,12,15]]},"abstract":"<jats:p>We report the outcome of reduced-intensity allogeneic progenitor cell transplantation (alloPCT) for 188 patients with lymphoma from the Working Party Lymphoma of the European Group for Blood and Bone Marrow Transplantation (EBMT). The median age of the patients was 40 years, the median number of prior treatment courses was 3, and 48% of patients had undergone a prior autologous transplantation. Eighty-four percent of the patients received conditioning with fludarabine-based regimens and 10% with the BEAM (BCNU, etoposide, cytosine arabinoside, melphalan) protocol. Full donor chimerism was confirmed in 71% of 100 patients assessed. Acute graft-versus-host disease (GVHD) developed in 37% of patients and chronic GVHD in 17%. A disease response to donor leukocyte infusion (DLI) was seen in 10 of 14 patients. With a median follow-up of 283 days, the overall survival rates at 1 and 2 years were 62% and 50%, respectively. The 100-day and 1-year transplantation-related mortality (TRM) rates were 12.8% and 25.5%, respectively, and were significantly worse for older patients. The probability of disease progression at 1 year for patients with chemoresistant and chemosensitive disease were 75% and 25%, respectively (P\u2009=\u2009.001). The progression-free survival at 1 year was 46% and was significantly better for those with chemosensitive disease, Hodgkin disease (HD), and low-grade non-Hodgkin lymphoma (NHL). Patients with high-grade NHL, mantle cell lymphoma, or chemoresistant disease had a poor outcome. Reduced-intensity progenitor cell transplantation is associated with a reduced TRM and may control advanced HD and low-grade NHL. A longer period of follow-up is required to determine the benefit of DLI and the graft-versus-lymphoma effect.<\/jats:p>","DOI":"10.1182\/blood-2001-11-0107","type":"journal-article","created":{"date-parts":[[2002,11,26]],"date-time":"2002-11-26T18:42:38Z","timestamp":1038336158000},"page":"4310-4316","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":323,"title":["Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation"],"prefix":"10.1182","volume":"100","author":[{"given":"Stephen P.","family":"Robinson","sequence":"first","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony H.","family":"Goldstone","sequence":"additional","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mackinnon","sequence":"additional","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Carella","sequence":"additional","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Russell","sequence":"additional","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Ruiz","family":"de Elvira","sequence":"additional","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goli","family":"Taghipour","sequence":"additional","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[{"name":"From the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (see  for contributing centers)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111821014243800_B1","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma.","volume":"92","author":"Van Besien","year":"1998","journal-title":"Blood."},{"key":"2019111821014243800_B2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.","volume":"77","author":"Jones","year":"1991","journal-title":"Blood."},{"key":"2019111821014243800_B3","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood.V73.7.1749.1749","article-title":"Bone marrow transplantation in the treatment of patients with lymphoma.","volume":"73","author":"Armitage","year":"1989","journal-title":"Blood."},{"key":"2019111821014243800_B4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1700989","article-title":"Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation.","volume":"20","author":"Tsai","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"2019111821014243800_B5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/sj.bmt.1701918","article-title":"Allogeneic bone marrow transplant or second autograft in patients who relapse after an autograft.","volume":"24","author":"Ringden","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"2019111821014243800_B6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Anti-leukemic effect of graft-versus-host disease in recipients of allogeneic marrow grafts.","volume":"300","author":"Weiden","year":"1979","journal-title":"N Engl J Med."},{"key":"2019111821014243800_B7","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case controlled analysis of the European Bone Marrow Transplant Group registry data.","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol."},{"key":"2019111821014243800_B8","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(05)60328-5","article-title":"Graft-versus-lymphoma effect of donor leucocyte infusions shown by real-time quantitative PCR analysis of t(14;18) [letter].","volume":"352","author":"Mandigers","year":"1998","journal-title":"Lancet."},{"key":"2019111821014243800_B9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)11135-2","article-title":"Mixed lymphohematopoietic chimerism and graft-versus-host-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone marrow transplantation.","volume":"353","author":"Sykes","year":"1999","journal-title":"Lancet."},{"key":"2019111821014243800_B10","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies.","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol."},{"key":"2019111821014243800_B11","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analogue-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood."},{"key":"2019111821014243800_B12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood."},{"key":"2019111821014243800_B13","doi-asserted-by":"crossref","first-page":"24192425","DOI":"10.1182\/blood.V96.7.2419","article-title":"In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.","volume":"96","author":"Kottaridis","year":"2000","journal-title":"Blood."},{"key":"2019111821014243800_B14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood."},{"key":"2019111821014243800_B15","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol."},{"key":"2019111821014243800_B16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","article-title":"Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.","volume":"25","author":"Nagler","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"2019111821014243800_B17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.bmt.1702580","article-title":"Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.","volume":"26","author":"Anderlini","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"2019111821014243800_B18","doi-asserted-by":"crossref","first-page":"42014205","DOI":"10.1182\/blood.V90.10.4201","article-title":"Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.","volume":"90","author":"Verdonck","year":"1997","journal-title":"Blood."},{"key":"2019111821014243800_B19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0140-6736(91)90609-S","article-title":"GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen.","volume":"338","author":"Laporte","year":"1991","journal-title":"Lancet."},{"key":"2019111821014243800_B20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/146532401753174034","article-title":"Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+\/\u2212) fludarabine conditioning combined with post-transplant donor-lymphocyte infusion.","volume":"3","author":"Lush","year":"2001","journal-title":"Cytotherapy."},{"key":"2019111821014243800_B21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1423-0410.1998.tb05438.x","article-title":"Donor leukocyte transfusions for treatment of leukaemic relapse after bone marrow transplantation.","volume":"74(suppl 2)","author":"Kolb","year":"1998","journal-title":"Vox Sang."},{"key":"2019111821014243800_B22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1046\/j.1365-2141.2000.02075.x","article-title":"Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation.","volume":"110","author":"Mackinnon","year":"2000","journal-title":"Br J Haematol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/13\/4310\/1255082\/h82402004310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/13\/4310\/1255082\/h82402004310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:01:53Z","timestamp":1574128913000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/13\/4310\/106033\/Chemoresistant-or-aggressive-lymphoma-predicts-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,15]]},"references-count":22,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2002,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2001-11-0107","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,12,15]]}}}